Skip to content
Company Analysis

HUTCHMED (China) Limited HCM

A comprehensive view of key metrics, scores, and financial health for HUTCHMED (China) Limited

Overview of HUTCHMED (China) Limited

HCM NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Mid Cap
HUTCHMED (China) Limited (HCM), is a Mid Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $13.27, about 21.1% overvalued vs fair value, -14.1% 1Y return, ranked 374/1145 in sector.
Metrics P/E 5.1× Rev Growth -13.0% ROE 45.7% Gross Margin 38.7%
USD 13.27
0.91%
(Delayed)
• Vol 90d: 48.6%
52-Week Range
Market Cap
$2.32B
Enterprise Value
$2.35B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Good
Efficiency
Weak
Valuation
Weak
Growth
Fair
Profitability
Good
Health
Good
Efficiency
Weak
Valuation
Weak
Completeness: 88%
Confidence: 92%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.hutch-med.com
HQ Hong Kong
Employees 1,780
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$10
$10
$11
Current: $13.27 -21% vs base

Engine Room Money Flow™

Mid Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$548.5M
-13%%
Gross Profit
$212.2M
-24.6%%
R&D Expense
$148.3M
-30.1%%
Operating Income (EBIT)
$501.6M
28316.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
-12.9%
Poor

Weak cash conversion - investigate working capital

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating HUTCHMED (China) Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
51
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.79), with robust interest coverage.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.87), providing operational cushion.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 35.0th percentile with high volatility suggests weak pricing power or commoditized products.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.27), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
29
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing HCM's balance between Growth (27.7%), Profitability (32.7%), and Safety (39.5%). Growth 28% Safety 40% Profitability 33%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

55th percentile vs peers
56
Key Signals
EPS Growth YoY 11.11 94p Revenue CAGR 3Y 8.8% 62p Rev Growth YoY -13.0% 22p TSR 27.4% 61p
Strengths
  • EPS Growth YoY in top 20% of peers (11.11, 94th percentile)
  • Interest Coverage Ratio in top 20% of peers (175.06, 99th percentile)
  • Superior capital returns - 2 return metrics above peer median
Risks

No significant risks identified for this axis.

Profitability

65th percentile vs peers
66
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

79th percentile vs peers
80
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for HUTCHMED (China) Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$10.47
- - -
-21.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000